medigraphic.com
Órgano Oficial del Instituto Nacional de Pediatría

2014, Number 4

<< Back Next >>

Acta Pediatr Mex 2014; 35 (4)

Obesity: assessment, diagnosis, treatment and opportunities for its prevention

Perea-Martínez A, López-Navarrete GE, Padrón-Martínez M, Lara-Campos AG, Santamaría-Arza C, Ynga-Durand MA, Peniche-Calderón J, Espinosa-Garamendi E, Ballesteros-del Olmo JC

Language: Spanish
References: 87
Page: 316-337
PDF size: 686.67 Kb.


ABSTRACT

Obesity is a public health problem in the world. Its impact and potential consequences on health and quality of life of individuals and their families, health systems and the global economy, has become a priority issue for governments and administrative systems. It is a multifactorial disease with well-known prenatal and postnatal origins, which offer prevention and treatment opportunities. So, is necessary the health professional have an intimate knowledge of the disease and its complications, also existing treatment options: behavior management for acquiring a healthy lifestyle, drugs, nutrients and bariatric surgery; to achieve contain the impact on healthy life years, life expectancy and occupational health worldwide.


REFERENCES

  1. http://www.who.int/mediacentre/factsheets/fs312/es/ index.html

  2. Garduño EJ, Morales CG, Martínez VS, Contreras HI, Flores HS, et al. Una mirada desde los servicios de salud a la nutrición de la niñez mexicana. III. Carga económica y en salud de la obesidad en niños mexicanos. Proyecciones de largo plazo. Bol Med Hosp Infant Mex 2008;65:49-56.

  3. Instituto Nacional de Salud Pública. Encuesta Nacional de Salud y Nutrición. 2012. Secretaría de Salud. México. 2012. Disponible en: http://ensanut.insp.mx/

  4. Sánchez-Muñoz F, García-Macedo R, Alarcón-Aguilar F, Cruz M. Adipocinas, tejido adiposo y su relación con células del sistema inmune. Gac Med Mex 2006;141:505-12.

  5. Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 2003;112:1785-8.

  6. Pittas AG, Joseph NA, Greenberg AS. Adipocytokines and insulin resistance. J Clin Endocrinol Metab 2004;89:447-52.

  7. Kiortsis DN. A review of the metabolic effects of controlledreleased Phentermine/Topiramate. Hormon 2013;12:507- 16.

  8. Kushner RF. Weight Loss Strategies for Treatment of Obesity. Prog Cardiovasc Dis 2014;56:465-72.

  9. Hashemipour M, Kelishadi R, Tavalaee ZS, Ghatreh SS. Effect of education on anthropometric indices in obese parents and children after one year of folow-up. Atheroscl J 2012;8:21-6.

  10. Nanri A, Tomita K, Matsushita Y, Ichikawa F, Yamamoto M, Nagafuchi Y, Kakumoto Y, Mizoue T. Effect of Six Months Lifestyle Intervention in Japanese Men with Metabolic Syndrome: Randomized Controlled Trial. J Occup Health 2012;54:215-22.

  11. Bergh I, Bjelland M, Grydeland M, Lien N, Andersen LF, Klepp KI, Anderssen SA, Ommundsen Y. Mid-way and postintervention effects on potential determinants of physical activity and sedentary behavior, results of the HEIA study – a culti-component school-based randomized trial. Int J Behav Nutr Phys Act 2012;9:63.

  12. Van Grieken A, Ezendam N, Paulis WD, van der Wouden, Raat H. primary prevention of overweight in children and adolescents: a meta-analysis of the effectiveness of interventions aiming to decrease sedentary behavior. Int J Behav Nutr Phys Act 2012;9:61.

  13. Norheim F, Gjelstad I, Hjorth M et al. Molecular Nutrition Research –The Modern Way Of Performing Nutritional Science. Nutrients 2012;4:1898-1944.

  14. Hoseim SM, Khosravi-Darani K, Mozafari MR. Nutritional and Medical Applications of Spirulina Microalgae. Mini-rev Med Chem 2013; 13: 1231-7.

  15. Perea MA, López NGE, Santamaría AC, Barrios FR, Reyes GU, Perea CAL, y cols. Nutrición y Obesidad. PAC/Academia Mexicana de Pediatría 2014. En Prensa.

  16. Serrano SA, Reynés MJ, Perea MA. Cuidar a la infancia… desde antes de nacer. México Social 1º Noviembre 2012.

  17. Adamo KB, Ferraro ZM, Brett KE. Can We Modify the Intrauterine Environment to Halt the Intergenerational Cycle of Obesity. Int J Environ Res Public health 2012;9:1263-1307.

  18. Alfaradhi MZ, Ozanne OE. Developmental programming in response to maternal overnutrition. Front Gen 2011;2:1- 13.

  19. Christian P, Stewart C. Maternal Micronutrient Deficiency, Fetal Development, and the Risk of Chronic Diseases. J Nutr 2010;140:437-45.

  20. González Hita ME, Ambrosio Macías KG, Sánchez Enríquez S. Regulación neuroendócrina del hambre, la saciedad y mantenimiento del balance energético. Inv Sal 2006;3:191-200.

  21. Barker DJP, Osmond C, Goldings J. Growth in utero, blood pressure in childhood and adult life, and mortality from cardiovascular disease. BMJ 1989;298:564-7.

  22. Barker DJP, Winter PD, Osmond C. Weight in infancy and death from ischaemic heart disease. Lancet 1989;2:577-80.

  23. Lucas A. Programming by early nutrition in man. Ciba Found Symp 1991;156:38-50.

  24. Ruager MR, Hyde MJ, Modi N. Maternal obesity and infant outcomes. J Early Hum Dev 2010;86:715-22.

  25. Guía de Práctica Clínica Para el Diagnóstico, Tratamiento y Prevención de Sobrepeso y Obesidad en el Adulto. México: Secretaria de Salud; 2008.

  26. Zarrati M, Shidfar F, Moradof M, Nasiri N, Keyvani H, Rezaei HM, Razmpoosh E. Relationship between breast feeding and obesity in children with low birth weight. Iran Red Crescent Med J 2013;15:676-82.

  27. Krebs N. F. Himes J. H. Jacobson D., et al. Assesment of Child and Adolescent Overweight and Obesity. Pediatrics 2007;120:S193.

  28. Prevención, Diagnóstico y tratamiento del Sobrepeso y la Obesidad Exógena. México, Secretaria de Salud, Actualización 2012.

  29. http://www.who.int/mediacentre/factsheets/fs311/es/

  30. http://www.cdc.gov/growthcharts/

  31. Ruano GM, Teruel VS, Aguirregoicoa GE, Criado GL, Duque LY, García-Blanch G. Nutrición, síndrome metabólico y obesidad mórbida. Nutr Hosp 2011;26:759-64.

  32. Purkayastha S, Cai D. Neuroinflammatory basis of metabolic syndrome. Mol Metab 2013;2:358-63.

  33. Reinehr T. Type 2 diabetes mellitus in children and adolescents. World J Diabetes 2013;4:270-81.

  34. Wolin KY, Carson K, Colints GA. Obesity and Cancer. The Oncologist 2010; 15:556-65.

  35. Michels KB, Barault L. Birth weight, maternal Weight Trajectories and Global DNA Methylation of LINE-1 Repetitive Elements. PLoS ONE 2011;6:e5254. doi:10.1371/ journal,pone.0025254

  36. D´Adamo E, Santoro N, Caprio S. Metabolic Syndrome in Pediatrics: Old Concepts Revised, New Concepts Discussed. Pediatr Clin N Am 2011;58:1241-1255.

  37. Flores HS, Klünder KM y López CN, Sobrepeso y Obesidad de los niños y adolescentes. Retos en sus causas, manejo y consecuencia. En: Nutrición y Gastroenterología pediátrica. Capítulo 15. México DF: McGraw Hill, 2013; pp. 140-160.

  38. Ananadacoomarasamy A, Caterson I, Sambrook P, Fransen M, March L. The impact of obesity on the musculoskeletal system. Int J Obesity 2008;32:211-222.

  39. Brumbaugh DE, Friedman JE. Developmental origins of nonalcoholic fatty liver disease. Pediatr Res 2014;75:140-7.

  40. Pacifico L, Nobili V, Anania C, Verdecchia P, Chiesa C. Pediatric nonalcoholic fatty liver disease, metabolic syndrome and cardiovascular risk. World J Gastroenterol 2011;17:3082-91.

  41. Bayard M, Holt J, Boroughs E. Nonalcoholic Fatty Liver Disease. Am Fam Phys 2006;73:1961-8.

  42. Wu YW, Tseng PH, Lee YC, Wang SY, Chiu HM, Tu CH, et al. Association of esophageal inflammation, obesity and gastroesophageal reflux disease:from FDG PET/CT perspective. PLoS One 2014;18:e92001

  43. Hall ME, do Carmo JM, da Silva AA, Juncos LA, Wang Z, Hall JE. Obesity hypertension, and chronic kidney disease. Int J Nephrol Renovasc Dis 2014;7:75-85.

  44. Young SK. Obesity Associated Hypertension: New Insights into Mechanism Electrol Blood Press 2013;11:46-52.

  45. Flynn JT, Daniels SR, Hayman LL, Maahs DM, McCrindle BW, Mitsnefes M, Zachariah JP, Urbina EM. Update: Ambulatory Blood Pressure Monitoring in Children and Adolescents: A Scientific Statement From the American Heart Association. Hypertension 2014;63:doi:10.1161/ HYP.0000000000000007.

  46. Kim T, Yang Q. Peroxisome-proliferator-activated receptors regulate redox signaling in the cardiovascular system. World J Cardiol 2013;26:164-74.

  47. Gregorio B, Athanazio RA, Vieira BA, Serra NF, Terese R, Hora F. Symptoms of obstructive sleep apnea-hypopnea syndrome in children. J Bras Pneumol 2008;34:356-61.

  48. Taveras EM, Rifas-Shiman S, Oken E, Gunderson EP, Gillman MW. Short Sleep Duration in Infancy and Risk of Childhood Overweight. Arch Pediatr Adolesc Med 2008;162:305-11.

  49. Elvia VML, Rodea ME, Jiménez EA, Quintana VS. Metabolic syndrome and its components among obese (BMI > 95th) Mexican Adolescents. Endocr Connect 2013;2:208-15.

  50. Kennedy MJ, Jellerson KD, Snow MZ, Zacchetti ML. Challenges in the pharmacologic management of obesity and secondary dyslipidemia in children and adolescents. Paediatr Drugs 2013;15:335-42.

  51. Vander Wal JS, Mitchell ER. Psychological Complications of Pediatric Obesity. Pediatr Clin N AM 2011;58:1393-1401.

  52. Bremer AA. Polycystic Ovary Syndrome in the Pediatric Population. Metabol Synd Rel Disorders 2010;8:375-394.

  53. Contreras MY, Bueno PJH. Hipertension intracranial Idiopática: análisis descriptivo en nuestro medio. Neurología 2013:doi:10.1016/j.nrl.2013.08.009.

  54. Odegaard JI, Chawla A. Leukocyte set points in metabolic disease. Biol Report 2012;4:13 doi:10.3410/84-13.

  55. Perea MA, Bárcena SE, Rodríguez HR, et al. Obesidad y sus comorbilidades en un grupo de niños y adolescentes asistidos en el Instituto Nacional de Pediatria. Act Pediatr Mex 2009;30:167-74.

  56. Perea MA, López PL, Bárcena SE, et al. Propuestas para la atención continua de niños y adolescentes obesos. Act Pediatr Mex 2009;30:54-68.

  57. Klünder-Klünder M., Flores-Huerta S. Waist circumference values according to height percentiles: A proposal to evaluate abdominal obesity en mexican children and adolescents between 6 and 16 years of age. Arch Med Res 2011;42:515-22.

  58. Rauner A, Mess F, Wolf A. The relationship between physical activity, physical fitness and overweight in adolescents: a systematic review of studies published in or after 2000. BMC Pediatrics 2013;13:19.

  59. Rivera JA, Muñoz-Hernández O, Rosas-Peralta M, Aguilar- Salinas C, Popkin BM, Willett WC. Consumo de bebidas para una vida saludable: Recomendaciones para la población mexicana. Sal Pub Mex 2008;50:173-95.

  60. Brufani C, Crino A, Fintini D, Ippolita PP, Cappa M, Manco M. Systematic Review of Metformin Use in Obese Nondiabetic Children and Adolescents. Horm Res Paediatr 2013;80:78- 85.

  61. McCrindle BW. Summary of the American Heart Association´s Scientific Statement on Drug Therapy of High-Risk lipid Abnormalities in Children and Adolescents. Arterioscler Thromb Vasc Biol 2007;27:982-5.

  62. Greydanus DE, Bricker LA, Feucht C. Pharmacotherapy for ObeseAdolescents. Pediatr Clin N Am 2011;58:139-53.

  63. Sherafat-Kazemzadeh R, Yanovski S, Yanovski JA. Pharmacotherapy for childhood obesity: present and future prospects. Int J Obesity 2013;37:1-15.

  64. Norheim F, Gjelstad I, Hjorth M et al. Molecular Nutrition Research –The Modern Way Of Performing Nutritional Science. Nutrients 2012;4:1898-1944.

  65. Riccioni G, D´Orazio N, Palumbo N, et al. Relationship between plasma antioxidant concentrations and carotid intima-media thickness: the Asymptomatic Carotid Atherosclerotic Disease In Manfredonia Study. Eur J Cardiovasc Prev Rehabil 2009;16:351-7.

  66. Pariza MW Perspective on safety and effectiveness of conjugated linoleic acid. Am J Clin Nutr 2004;79(suppl):1132S-6.

  67. Kennedy A, Martínez K, Schmidt S et al. Antiobesity Mechanisms of Action of Conjugated Linoleic Acid. J Nutr Biochem 2010;21:171-9.

  68. Teegarden D, Donkin SS. Vitamin D: emerging new roles in insulin sensitivity. Nutr Res Rev 2009;22:82-92.

  69. Danescu LG, Levy S, Levy J. Vitamin D and diabetes mellitus. Endocrine. 2009;35:11-7.

  70. Nagpal J, Pande JN, Bhartia A. A double blind, randomized, placebo-controlled trial of the short-term effect of vitamin D3 supplementation on insulin sensitivity in apparently healthy, middle-aged, centrally obese men. Diabet Med 2009;26:19-27.

  71. Holick MF. Vitamin D Status: Measurement, interpretation, and Clinical Application. Ann Epidemiol 2009;19:73–8.

  72. Grineva EN, Karonova T, Micheeva E, et al. Vitamin D Deficiency is a risk factor for obesity and diabetes type 2 in women at late reproductive age. Aging 2013;5:575-81.

  73. De Pergola G, Nitti A, Bartolomeo N, et al. Possible Role of hyperinsulinemia and Insulin Resistance in Lower Vitamin D Levels in Overweight and Obese Patients. Bio Med Res Int 2013.

  74. Kienreich K, Tomaschitz A, Verheyen N et al. Vitamin D and Cardiovascular Disease. Nutrients 2013;5:3005-21.

  75. Tai K, Need AG, Horowitz M, Chapman IM. Vitamin D, glucose, insulin, and insulin sensitivity. Nutrition 2008;24:279-85.

  76. The Society for Adolescent Health and Medicine. Recommended Vitamin D intake and Management of Low Vitamin D Status in Adolescents: A Position Statement of the Society for Adolescent Health and Medicine. Adolesc Health 2013;52:801-3.

  77. Plantinga Y, Ghiadoni L, Magagna A, et al. Supplementation with vitamin C and E improves arterial stiffness and endothelial function in essential hypertensive patients. Am J Hypertension 2007;20:392–7.

  78. Engler M et al. Antioxidant Vitamins C and e Improve Endothelial Function in Children with Hyperlipidemia: Endothelial Assessment of Risk from Lipid in Youth (EARLY) Trial. Circulation 2003;108:1059-63.

  79. Zemel MB, Bruckbauer A. Effects of a Leucine and Piridoxine-Containing Nutraceutical on fat Oxidation, and oxidative and Inflammatory Stress in Overweight and Obese Subjects. Nutrients 2012;4:529-41.

  80. Bai Y, Sun L, Yang T, Sun K, Chen J, Hui R. Increase in fasting vascular endothelial function after short-ter oral L-arginine is effective when baseline flow-mediated dilation is low: a meta-analysis of randomized controlled trials. Am J Clin Nutr 2009;89:77-88.

  81. Deng R, Chow T. Hypolipidemic, Antioxidant and Antiinflammatory Activities of Microalgae Spirulina. Cardiovasc Ther 2010; 28: e33-e45.

  82. Hua Y, Clark S, Ren J, Sreejayan N. Molecular Mechanisms of Chromium in Alleviating Insulin Resistance. J Nutr Biochem 2012; 23: 313-319.

  83. Mallappa RH et al. Management of metabolic syndrome through probiotic and prebiotic interventions. Indian J Endocrinol Metab 2012; 16: 20-7.

  84. Academy of Nutrition and Dietetics. Position of the Academy of Nutrition and Dietetics: Use of Nutritive and Nonnutritive Sweeteners. J Acad Nutr Diet 2012;112:739- 758.

  85. Sylvetsky A, Rother K, Brown R. Artificial Sweetener Use Among Children: Epidemiology, Recommendations, Metabolic Outcomes, and Future Directions. Pediatr Clin N Am 2011;58:1467-1480.

  86. Yang Q. Gain weight by “going diet”. Artificial sweeteners and the neurobiology of sugar cravings. Neuroscience 2010. Yale J Biol Med 2010;83:101-108.

  87. NORMA Oficial Mexicana NOM-043-SSA2-2012




2020     |     www.medigraphic.com